Search EN menu en EIB GROUP CLIENT PORTAL
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

    Signature(s)

    Amount
    € 100,000,000
    Countries
    Sector(s)
    Germany : € 100,000,000
    Industry : € 100,000,000
    Signature date(s)
    24/03/2025 : € 100,000,000

    Summary sheet

    Release date
    18 November 2024
    Status
    Reference
    Signed | 24/03/2025
    20240481
    Project name
    Promoter - financial intermediary
    DRAEGERWERK MEDICAL TECHNOLOGY
    DRAEGERWERK AG & CO KGAA
    Proposed EIB finance (Approximate amount)
    Total cost (Approximate amount)
    EUR 100 million
    EUR 248 million
    Location
    Sector(s)
    Description
    Objectives

    The project concerns the promoter's corporate R&D programme in its Medical Division for the period of 2025-2026 with a particular focus on connected health devices.

    The aim is to support R&D and new product improvements of critical care medical devices to be used in acute care departments.

    Additionality and Impact

    The financing of this project supports medical technology RDI activities which generate significant positive knowledge externalities through the creation of innovative processes, products, and services and through skills development. The financing will contribute to upgrading and improving medical treatment. The operation supports the development of connected medical devices within hospital environments, thus contributing to better workflows in acute care as the promoter is active in patient surveillance and monitoring. The promoter's research activities target investment gaps in medical technology. The Borrower is a relatively small sized company and competing on a global scale against large non-EU conglomerates. The EIB provides access to financing on a long-term basis that will allow the Borrower to pursue medical RDI investments which by nature span over longer periods and for which financial success is more uncertain.


    Environmental aspects
    Procurement

    The project concerns investments in that are expected to be carried out in existing facilities, already authorised, and which would therefore not require an environmental impact assessment (EIA) 2014/52/EU amending the EIA Directive 2011/92/EC.

    The promoter is a private company not operating in the utilities sector, and is thus not covered by EU directives on procurement.

    Milestone
    Under appraisal
    Approved
    Signed
    17 December 2024
    24 March 2025

    Disclaimer

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
    They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Documents

    Environmental and Social Data Sheet (ESDS) - DRAEGERWERK MEDICAL TECHNOLOGY
    Publication Date
    19 Dec 2024
    Document language
    Main Topic
    Lending
    Document Number
    235498674
    Document Focus
    Environmental Information
    Project Number
    20240481
    Sector(s)
    Regions
    Countries
    Publicly available
    Download now

    General enquiries and comments

    The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
    Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
    Alternatively, the EIB can be contacted through its external offices.
    Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

    Media enquiries

    Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

    Complaints mechanism

    Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

    Zero tolerance against fraud and corruption

    The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Investigations Division. All reports will be treated as strictly confidential and handled in line with EIB investigation procedures and the EIB Group Anti-Fraud Policy.

    Related publications